EDGE
Book a demo

All Updates

Filter
Funding
Filament Health to raise CAD 2.5 million via private placement
Psychedelic Medicine
Jun 30
Last week:
Regulation/policy
California Senator pushes psychedelic legalization bill to next year
Psychedelic Medicine
Aug 12
M&A
Funding
Management news
Field Trip completes spinout transaction; raises CAD 20 million in private placements
Psychedelic Medicine
Aug 11
Earnings/results
MindMed reports clinical trials progress; expects Phase IIb results in 2023
Psychedelic Medicine
Aug 11
Partnerships
Lobe Sciences partners with iNGENu to conduct clinical trials in Australia
Psychedelic Medicine
Aug 10
Earnings/results
Cybin commences Phase I/IIa trial of CYB003; announces USD 35 million equity program
Psychedelic Medicine
Aug 8
Listing
Field Trip Health & Wellness Ltd to list on Toronto Stock Exchange
Psychedelic Medicine
Aug 4
M&A
Geographic expansion
Braxia Scientific acquires KetaMD; enters US market
Psychedelic Medicine
Aug 3
Funding
HAVN Life Sciences to raise CAD 9 million from Alpha Blue Ocean
Psychedelic Medicine
Jul 21
Funding
Awakn Life Sciences receives UK government funding for Phase III trial
Psychedelic Medicine
Jul 20
Management news
Compass Pathways appoints Kabir Nath as new CEO
Psychedelic Medicine
Jul 19
Earnings/results
Awakn to offer ketamine-assisted therapy in clinics across North America
Psychedelic Medicine
Jul 15
Earnings/results
Numinus reports increased clinic revenue in Q3; expands clinic network via Novamind acquisition
Psychedelic Medicine
Jul 14
Funding
Tryp Therapeutics closes third tranche of private placement with CAD 0.2 million
Psychedelic Medicine
Jul 8
Earnings/results
Field Trip Health FY2022 update: Clinic network expands to 12, lower than original target
Psychedelic Medicine
Jun 29
Earnings/results
Cybin reports full-year 2022 results
Psychedelic Medicine
Jun 22
Earnings/results
Wellbeing Digital Sciences releases Q3 2022 results
Psychedelic Medicine
Jun 16
Funding
Revitalist raises CAD 3.9 million in private placement
Psychedelic Medicine
Jun 15
Earnings/results
Awakn Life Sciences releases financial results for Q1 2022
Psychedelic Medicine
Jun 14
M&A
Geographic expansion
Numinus Wellness completes acquisition of Novamind; enters US market
Psychedelic Medicine
Jun 10
Funding
Innerwell launches from stealth, raising USD 3 million in pre-seed funding
Psychedelic Medicine
Jun 3
Funding
Tripp raises USD 11.2 million in Series A funding; acquires Eden
Psychedelic Medicine
Jun 1
M&A
Silo Wellness to acquire Dyscovry Science; enters drug development space
Psychedelic Medicine
May 31
Earnings/results
Wesana Health releases Q1 2022 financial results
Psychedelic Medicine
May 31
Earnings/results
Novamind achieves record revenue of CAD 3.2 million in Q3 2022
Psychedelic Medicine
May 31
Earnings/results
PsyBio Therapeutics provides clinical update for Q1 2022
Psychedelic Medicine
May 30
Funding
Mydecine closes overnight marketed public offering with CAD 2.8 million
Psychedelic Medicine
May 27
M&A
Mycotopia Therapies to merge with Ei.Ventures to form PSLY.COM
Psychedelic Medicine
May 23
Partnerships
Beckley Psytech partners with Empatica for digitalized clinical trial support
Psychedelic Medicine
May 19
Funding
Mydecine to raise CAD 4 million in overnight marketed public offering
Psychedelic Medicine
May 19
Psychedelic Medicine

Psychedelic Medicine

Jun 30

Filament Health to raise CAD 2.5 million via private placement

Funding

  • Vancouver-based psychedelic extraction and drug discovery company Filament Health has announced a non-brokered private placement of 1,250 convertible debenture units at a rate of CAD 1,000 (USD 773) per unit to raise CAD 1.25 million (USD 1 million) and a non-brokered private placement of 9.6 million units at a rate of CAD 0.13 (USD 0.1) per unit to raise CAD 1.25 million (USD 1 million). The gross proceeds of the two offerings amounted to CAD 2.5 million (USD 2 million).

  • Each debenture unit will consist of non-interest bearing, unsecured convertible debentures worth CAD 1,000 (USD 773)—convertible into common shares at a rate of CAD 0.25 (USD 0.19)—and 6,667 warrants that enable the purchase of one common share for a period of 36 months following the placement closing date, at a rate of CAD 0.30 (USD 0.23). 

  • Each unit will consist of one common share and one common share purchase warrant. Each warrant will enable the purchase of one additional share for a period of 36 months following the closing date at a rate of CAD 0.30 (USD 0.23).

  • The net proceeds of the placement will be used to fuel the company’s R&D efforts, intellectual property, and general working capital purposes. Subject to the final approval from NEO Exchange, the placement is expected to close on or about July 14, 2022.

Sign-up for a free trial

Gain access to all industry hubs, market maps, research tools, and more
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.